7.72
0.00%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mabion
Its shares trade on GPW under the ticker MAB.WA. It has been listed since 10 August 2010. In the fiscal year to 31 December 2025, it reported revenue of PLN 15.8m and a net loss of PLN 62.6m. At that date it held total assets of PLN 110.4m and shareholders' equity of PLN 48.8m.
Mabion SA engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Aug 2010
- Employees
- 255
- Website
- mabion.eu ↗
Leadership
Pay as last reported
- Mr. Robert KonskiIndependent Chairman of the Supervisory Board, since 2017PLN 93,200
- Mr. Gregor KawaletzPresident of the Management Board
- Mr. Jozef BanachIndependent Deputy Chairman of the Supervisory Board, since 2023PLN 93,200
- Mr. Detlef BehrensMember of the Management Board for Business
- Mr. Joaquin BenitoMember of the Management Board - Transformation
- Mr. Przemyslaw MencelIndependent Member of the Supervisory Board
- Mr. Mateusz Rosa-GawalkiewiczIndependent Member of the Supervisory Board
- Mr. Wojciech WoskoMember of the Supervisory BoardPLN 59,700
- Mr. Michal WierzchowskiIR Contact Officer, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mabion SA develops humanized monoclonal antibodies for oncology and autoimmune diseases.
- The company operates its own R&D Center in Lodz Special Economic Zone, Poland.
- Mabion SA was founded by four pharmaceutical companies and two biotech R&D firms.
Weaknesses
- Mabion SA has 255 employees, which is a small workforce for biotech development.
- The company's IPO was on 10 August 2010, indicating limited market experience.
- Mabion SA focuses solely on oncology and autoimmune disease treatments.
Opportunities
- Poland's Special Economic Zone in Lodz offers tax incentives for biotech firms.
- The global biotech market for monoclonal antibodies is growing rapidly.
- Mabion SA can expand its product portfolio into new therapeutic areas.
Threats
- Mabion SA faces competition from larger biotech firms in the global market.
- The company's reliance on a single therapeutic area increases market risk.
- Regulatory changes in the European Union could impact biotech drug approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.